BCLI Live signals | Maximize Profits with Getagraph.com

BUY 102141 min ago

@ $0.370

Issued: 9 Feb 2024 @ 09:30

Return: 43.74%

Previous signal: Feb 8 - 14:29

Previous signal: Sell

Return: -6.68 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases...

Stats
Today's Volume	996 550
Average Volume	1.01M
Market Cap	36.36M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.0700 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.330
ATR14	$0.00300 (0.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Lebovits Chaim	Buy	115 072	Common Stock
2024-04-17	Lebovits Chaim	Buy	130 000	Common Stock
2024-03-11	Lindborg Stacy	Buy	241 935	Common Stock
2024-03-11	Yablonka Uri	Buy	109 426	Common Stock
2024-03-11	Patlis Alla	Buy	65 246	Common Stock

INSIDER POWER
100.00
Last 91 transactions
Buy: 3 104 128 \| Sell: 254 714

Volume Correlation

Long: 0.25 (neutral)

Short: -0.10 (neutral)

Signal:(58.608) Neutral

Brainstorm Cell Correlation

10 Most Positive Correlations
INTU	0.828
ECOR	0.811
TROO	0.81
USMC	0.81
ESPO	0.804
ADBE	0.803
XENT	0.803

10 Most Negative Correlations
CYRN	-0.828

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Brainstorm Cell Correlation - Currency/Commodity

0.30
( neutral )

0.29
( neutral )

0.00
( neutral )

0.28
( neutral )

0.00
( neutral )

-0.42
( neutral )

Brainstorm Cell Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-265 000 (0.00 %)
EPS:	$-0.400

Q4	2023
Revenue:	$0
Gross Profit:	$-66 000.00 (0.00 %)
EPS:	$-0.110

Q3	2023
Revenue:	$0
Gross Profit:	$-65 000.00 (0.00 %)
EPS:	$-0.0277

Q2	2023
Revenue:	$154 000
Gross Profit:	$87 000.00 (56.49 %)
EPS:	$-0.130

Financial Reports:

No articles found.

Brainstorm Cell

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.